Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer

• Published in: Biomedicine & pharmacotherapy Vol. 120; p. 109490
• Main Authors: Quan, Yongjun, Lei, Hongen, Wahafu, Wasilijiang, Liu, Yuexin, Ping, Hao, Zhang, Xiaodong
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.12.2019
• Subjects: Androgen Antagonists - pharmacology; Androgen receptor; Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Autophagy - drug effects; Autophagy inhibitor; Bladder cancer; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Drug Resistance, Neoplasm - drug effects; Enzalutamide; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins - metabolism; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - pharmacology; Receptors, Androgen - metabolism; Signal Transduction - drug effects; Urinary Bladder Neoplasms - drug therapy; Urinary Bladder Neoplasms - metabolism; RT; TURBT; DMSO; EtOH; KLK3; KLK2; Enzalutamide; BBN; ENZ; DHT; TUNEL; ANOVA; Autophagy inhibitor; FBS; mTOR; CCK-8; qPCR; cDNA; LSD; LC3; ATG5; PBS; SDS; BAF; p62; PVDF; Bladder cancer; ATG12; CQ; AR; nc; Androgen receptor; AMPK; 3-MA; ULK1; SEM; HE

[Display omitted] •Enzalutamide stimulates autophagy flux in J82 and T24 cell lines.•Monotherapy of enzalutamide failed to stimulates significant apoptosis in J82 and T24 cell lines.•Concurrent treatment of enzalutamide and autophagy inhibitors triggered apoptosis of bladder cancers in vitro and in...